LB Pharmaceuticals, Inc. (LBRX)
39.42
+0.19
(+0.48%)
USD |
NASDAQ |
Oct 22, 16:00
39.77
+0.35
(+0.89%)
After-Hours: 20:00
LB Pharmaceuticals Debt to Equity Ratio : 0.0157 for June 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0157 |
| March 31, 2026 | 0.0092 |
| December 31, 2025 | 0.0118 |
| September 30, 2025 | 0.0118 |
| June 30, 2025 |
| Date | Value |
|---|---|
| March 31, 2025 | |
| December 31, 2024 | 0.1879 |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Ligand Pharmaceuticals, Inc. | 1.169 |
| ANI Pharmaceuticals, Inc. | 1.022 |
| Corcept Therapeutics, Inc. | 0.0133 |
| Veru, Inc. | 0.0945 |
| Johnson & Johnson | 0.5477 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 361.69M |
| Total Liabilities (Quarterly) | 29.34M |
| Shareholders Equity (Quarterly) | 332.35M |
| Current Ratio | 15.08 |
| Net Debt Paydown Yield | -0.11% |